Adicet Bio Reports Data From Ongoing ADI-001 Phase 1 Trial In Patients With Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Portfolio Pulse from Benzinga Newsdesk
Adicet Bio reports positive data from its ongoing ADI-001 Phase 1 trial in patients with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. The trial demonstrated a 71% overall response rate and 63% complete response rate across all dose levels.
June 26, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Adicet Bio's ADI-001 Phase 1 trial demonstrates positive results in patients with aggressive B-cell non-Hodgkin's lymphoma, potentially boosting the company's stock price.
The positive results from the ongoing ADI-001 Phase 1 trial indicate that the treatment is effective in patients with aggressive B-cell non-Hodgkin's lymphoma. This news is likely to be well-received by investors, potentially leading to an increase in Adicet Bio's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100